


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of claims:

1. (Currently Amended) A method for treating ~~or preventing a disease~~ cancer, comprising modulating the activity of more than one protein kinase, comprising administering to a patient in need thereof an effective amount of the compound of having the structure:



or a pharmaceutically acceptable salt thereof, wherein:

A is a direct bond, ~~(CH₂)_a, (CH₂)_bCH=CH(CH₂)_e, or (CH₂)_bC≡C(CH₂)_e~~;

R₁ is aryl, heteroaryl or heterocycle fused to phenyl, each being optionally substituted with one to four substituents independently selected from R₃;

R₂ is -R₃, -R₄, -(CH₂)_bC(=O)R₅, -(CH₂)_bC(=O)OR₅, -(CH₂)_bC(=O)NR₅R₆,
-(CH₂)_bC(=O)NR₅(CH₂)_cC(=O)R₆, -(CH₂)_bNR₅C(=O)R₆,
-(CH₂)_bNR₅C(=O)NR₆R₇, -(CH₂)_bNR₅R₆, -(CH₂)_bOR₅,
-(CH₂)_bSO_dR₅ or -(CH₂)_bSO₂NR₅R₆;

a is 1, 2, 3, 4, 5 or 6;

b and c are the same or different and at each occurrence independently selected from 0, 1, 2, 3 or 4;

d is at each occurrence 0, 1 or 2;

R₃ is at each occurrence independently halogen, hydroxy, carboxy, alkyl, alkoxy, haloalkyl, acyloxy, thioalkyl, sulfinylalkyl, sulfonylalkyl, hydroxyalkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heterocycle, substituted heterocycle, heterocyclealkyl, substituted heterocyclealkyl, -C(=O)OR₈, -OC(=O)R₈, -C(=O)NR₈R₉, -C(=O)NR₈OR₉, -SO₂NR₈R₉, -NR₈SO₂R₉, -CN, -NO₂, -NR₈R₉, -NR₈C(=O)R₉, -NR₈C(=O)(CH₂)_bOR₉, -NR₈C(=O)(CH₂)_bR₉, -O(CH₂)_bNR₈R₉, or heterocycle fused to phenyl;

R₄ is alkyl, aryl, arylalkyl, heterocycle or heterocyclealkyl, each being optionally substituted with one to four substituents independently selected from R₃, or R₄ is halogen or hydroxy;

R₅, R₆ and R₇ are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle or heterocyclealkyl, wherein each of R₅, R₆ and R₇ are

optionally substituted with one to four substituents independently selected from R₃;
and

R₈ and R₉ are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle, or heterocyclealkyl, or R₈ and R₉ taken together with the atom or atoms to which they are bonded form a heterocycle, wherein each of R₈, R₉, and R₈ and R₉ taken together to form a heterocycle are optionally substituted with one to four substituents independently selected from R₃.

2. (Canceled)

3. (Original) The method of claim 1 wherein R₁ is aryl optionally substituted with one to four substituents independently selected from R₃.

4. (Withdrawn) The method of claim 1 wherein R₁ is heteroaryl optionally substituted with one to four substituents independently selected from R₃.

5. (Original) The method of claim 1 wherein R₄ is substituted heterocycle.

6. (Withdrawn) The method of claim 1 wherein R₄ is 3-triazolyl, optionally substituted at its 5-position with:

(a) a C₁-C₄ straight or branched chain alkyl group optionally substituted with a hydroxyl, methylamino, dimethylamino or 1-pyrrolidinyl group; or

(b) a 2-pyrrolidinyl group.

7. (Original) The method of claim 1, wherein -A-R₁ is phenyl, optionally substituted with one to four substituents independently selected from halogen, alkoxy, -NR₈C(=O)R₉, -C(=O)NR₈R₉, and -O(CH₂)_bNR₈R₉, wherein *b* is 2 or 3.

8. (Original) The method of claim 1, wherein the protein kinase is a protein tyrosine kinase.

9. (Original) The method of claim 1, wherein the activity of the protein kinases are simultaneously modulated.

10. (Original) The method of claim 9, wherein the activities of the protein kinases are simultaneously inhibited.

11. (Original) The method of claim 1, wherein the protein kinase is Aurora-A, AKT, CDK1/cyclinB(h), CDK2/cyclinA(h), CDK3/cyclinE(h), CDK5/p35(h), CDK6/cyclinD3(h), CDK7/cyclinH/MAT1, CHK1, CHK2, EGFR, c-RAF, RAS, cSRC, Yes, Fyn, Lck, Fes, Lyn, Syk, Bmx, FGFR3, GSK3 α , GSK3 β , PI3, IGF-1R, MAPK2, MAPKAP-K2, JNK, MEK1, p70S6K, PAK2, PDGFR α , PDGFR β , PDK1, PKA, PKC ϵ , PKC μ , PKD2, VEGF, PRAK, PRK2, ROCK-II, Rsk1, Rsk2, Rsk3 or SGK.

12. (Original) The method of claim 8, wherein the activities of the protein tyrosine kinases are selectively inhibited over non-tyrosine kinases.
13. (Original) The method of claim 1, wherein the activities of Auroa-A, Blk, CDK1, CDK2, CDK3, CDK5, CDK6, CHK1, CHK2, Src family of kinases, cSrc, Yes, Fyn, Lck, Fes, , Lyn, Syk, , FGF-R3, GSK3a, GSK3b, MAPK family including JNK, MEK, p70S6K, PKCmu, PKD2, PRAK, PRK2, ROCK-II, RSK1, RSK2 and RSK3 are selectively modulated over other kinases.
14. (Original) The method of claim 13, wherein the modulation is inhibition.
15. (Original) The method of claim 1, wherein the disease is an anti-proliferative disease.
16. (Original) The method of claim 15, wherein the anti-proliferative disease is cancer.
17. (Original) The method of claim 16, wherein the cancer is of the head, neck, eye, mouth, throat, esophagus, chest, bone, lung, colon, rectum, stomach, prostate, breast, ovaries, testicles or other reproductive organs, skin, thyroid, blood, lymph nodes, kidney, liver, pancreas, and brain or central nervous system
18. (Withdrawn) The method of claim 1, wherein the disease is an inflammatory disease.
19. (Withdrawn) The method of claim 18, wherein the inflammatory disease is hereditary obesity, dietary obesity, hormone related obesity, obesity related to the administration of medication, Type I diabetes, diabetes insipidus, diabetes mellitus, maturity-onset diabetes, juvenile diabetes, insulin-dependant diabetes, non-insulin dependant diabetes, malnutrition-related diabetes, ketosis-prone diabetes, ketosis-resistant diabetes, hearing loss, otitis externa, acute otitis media, chronic obstructive pulmonary disease, pulmonary interstitial fibrosis, acute respiratory distress syndrome, renal fibrosis, liver fibrosis, cystic fibrosis, wound-healing, burn-healing, allergy, allergic rhinitis, acute respiratory distress syndrome, systemic lupus erythematosus, nephropathy, pancreatitis, peritonitis or ischemia-reperfusion injury.
20. (Withdrawn) The method of claim 1, wherein the disease is a liver disease.
21. (Withdrawn) The method of claim 20, wherein the liver disease is hepatitis, alcohol-induced liver disease, toxin-induced liver disease, steatosis or sclerosis.
22. (Withdrawn) The method of claim 1, wherein the disease is a cardiovascular disease.

23. (Withdrawn) The method of claim 22, wherein the cardiovascular disease is atherosclerosis, restenosis following angioplasty, left ventricular hypertrophy, myocardial infarction, chronic obstructive pulmonary disease or stroke.

24. (Withdrawn) The method of claim 1, wherein the disease is a neurodegenerative disease.

25. (Withdrawn) The method of claim 24, wherein the neurodegenerative disease is epilepsy, Alzheimer's disease, Huntington's disease, Amyotrophic lateral sclerosis, peripheral neuropathies, spinal cord damage, AIDS dementia complex or Parkinson's disease.